Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability.

@article{Alqahtani2015DevelopmentOA,
  title={Development of a physiologically based pharmacokinetic/pharmacodynamic model to identify mechanisms contributing to entacapone low bioavailability.},
  author={Saeed Ibrahim Alqahtani and Amal Kaddoumi},
  journal={Biopharmaceutics & drug disposition},
  year={2015},
  volume={36 9},
  pages={587-602}
}
Entacapone is an inhibitor of catechol-O-methyltransferase (COMT) and is being used to extend the therapeutic effect of levodopa in patients with advanced and fluctuating Parkinson's disease. Entacapone has low and variable oral bioavailability and the underlying mechanism(s) for this behavior have not been studied. To explain such behavior and to… CONTINUE READING